Sato Yuichiro, Zhang Yuan-Wei, Androutsellis-Theotokis Andreas, Rudnick Gary
Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520-8066, USA.
J Biol Chem. 2004 May 28;279(22):22926-33. doi: 10.1074/jbc.M312194200. Epub 2004 Mar 25.
The second transmembrane domain (TM2) of neurotransmitter transporters has been invoked to control oligomerization and surface expression. This transmembrane domain lies between TM1 and TM3, which have both been proposed to contain residues that contribute to the substrate binding site. Rat serotonin transporter (SERT) TM2 was investigated by cysteine scanning mutagenesis. Six mutants in which cysteine replaced an endogenous TM2 residue had low transport activity, and two were inactive. Most of the reduction in transport activity was due to decreased surface expression. In contrast, M124C and G128C showed increased activity and surface expression. Random mutagenesis at positions 124 and 128 revealed that hydrophobic residues at these positions also increased activity. When modeled as an alpha-helix, positions where mutation to cysteine strongly affects expression levels clustered on the face of TM2 surrounding the leucine heptad repeat conserved within this transporter family. 2-(Aminoethyl)-methanethiosulfonate hydrobromide (MTSEA)-biotin labeled A116C and Y136C but not F117C, M135C, or Y134C, suggesting that these residues may delimit the transmembrane domain. None of the cysteine substitution mutants from 117 through 135 were sensitive to [2-(trimethylammonium)ethyl]methanethiosulfonate bromide (MTSET) or MTSEA. However, treatment with MTSEA increased 5-hydroxytryptamine transport by A116C. Activation of A116C by MTSEA was observed only in mutants containing Cys to Ile mutation at position 357, suggesting that modification of Cys-116 activated transport by compensating for a disruption in transport in response to Cys-357 replacement. The reactivity of A116C toward MTSEA was substantially increased in the presence of substrates but not inhibitors. This increase required Na+ and Cl-, and was likely to result from conformational changes during the transport process.
神经递质转运体的第二个跨膜结构域(TM2)被认为可控制寡聚化和表面表达。该跨膜结构域位于TM1和TM3之间,有人提出这两个结构域都含有对底物结合位点有贡献的残基。通过半胱氨酸扫描诱变研究了大鼠血清素转运体(SERT)的TM2。六个半胱氨酸取代内源性TM2残基的突变体具有低转运活性,两个无活性。转运活性的大部分降低是由于表面表达减少。相反,M124C和G128C表现出活性和表面表达增加。在124和128位的随机诱变表明这些位置的疏水残基也增加了活性。当建模为α-螺旋时,突变为半胱氨酸强烈影响表达水平的位置聚集在该转运体家族中保守的亮氨酸七肽重复序列周围的TM2面上。2-(氨基乙基)-甲硫基磺酸盐氢溴酸盐(MTSEA)-生物素标记了A116C和Y136C,但未标记F117C、M135C或Y134C,表明这些残基可能界定了跨膜结构域。从117到135的半胱氨酸替代突变体均对[2-(三甲基铵)乙基]甲硫基磺酸盐溴化物(MTSET)或MTSEA不敏感。然而,用MTSEA处理可增加A116C的5-羟色胺转运。仅在357位含有半胱氨酸到异亮氨酸突变的突变体中观察到MTSEA对A116C的激活,这表明半胱氨酸-116的修饰通过补偿因半胱氨酸-357替代而导致的转运破坏来激活转运。在底物存在下但在抑制剂不存在下,A116C对MTSEA的反应性显著增加。这种增加需要Na +和Cl-,并且可能是由转运过程中的构象变化引起的。